Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis entails substantial morbidity and mortality, yet no epidemiologic evidence exists on its outcomes in Mexico. This study assessed national hospitalizations (2005–2022) and mortality (2000–2022) related to ANCA-associated vasculitis using data from the General Board of Health Information. We extracted hospital discharges and deaths classified under ICD-10 M31.3 and M31.7, computing age-standardized hospitalization (ASHR) and mortality (ASMR) rates per 100,000 persons, overall and by sex. Annual percentage change (APC) and average annual percent change (AAPC) were estimated with Joinpoint regression. We identified 2,804 hospitalizations and 599 deaths. Females accounted for 50.3% of hospitalizations, while males represented 48.7% of deaths. Although overall ASHR and ASMR AAPCs were not statistically significant, notable trends emerged. From 2010 to 2022, ASHR declined significantly (APC: −5.2%; 95% CI: −9.7, −0.5; p=0.03), whereas mortality rates remained stable from 2000 to 2022 (AAPC: +3%; 95% CI: −4.6, 11.3; p=0.45). Nevertheless, mortality increased among males (APC: +6.4%; 95% CI: 0.9, 12.2; p=0.02) and individuals over 45 years (APC: +8.6%; 95% CI: 1.7, 16.0; p=0.02) from 2008 onward. Overall, these findings indicate no major changes in national rates, but reveal a decline in hospitalizations since 2010 and a rise in mortality for specific subgroups since 2008. Targeted interventions, particularly for older adults and men, appear warranted to address this evolving disease burden. Future research should explore underlying risk factors and evaluate tailored strategies to improve clinical outcomes in ANCA-associated vasculitis across Mexico. These insights may guide policy decisions and contribute to improved patient management nationwide.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used (or will use) ONLY openly available human data that were originally located at:http://www.dgis.salud.gob.mx/contenidos/basesdedatos/BD_Cubos_gobmx.html

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors